MetaCap

Acumen Pharmaceuticals (ABOS) vs Passage Bio (PASG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Passage Bio (PASG) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, losing 49.3% versus a loss of 88.1%. Over five years, PASG leads with a -97.3% price change compared with -97.7% for ABOS. Acumen Pharmaceuticals is the larger company by market cap ($13.5 million vs $12.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABOS-88.12%PASG-49.32%
+169%+34%-100%
Nov 21, 20251 yearNov 20, 2026
ABOS-98.11%PASG-97.66%
+7%-48%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABOS versus PASG key metrics
MetricABOSPASG
Share price$0.1865$3.92
Market cap$13.49M$12.61M
1-day change-3.52%+11.68%
YTD return-91.16%-66.78%
1-year return-88.12%-49.32%
5-year return-97.74%-97.30%
EPS (TTM)$-1.55$-10.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-121.33M$-45.52M
52-week high$3.60$20.00
52-week low$0.16$3.29
Distance from 52-week high-94.82%-80.40%
Analyst consensusstrong_buybuy
Avg. price target upside+3975.07%+295.41%
Average volume2.73M20.77K
Shares outstanding72.33M3.22M
Employees6024
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PASG has outperformed ABOS by 38.8 percentage points over the past year.

About Acumen Pharmaceuticals

ABOS stock →

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees

About Passage Bio

PASG stock →

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 24 employees

ABOS vs PASG FAQ

Which is bigger, Acumen Pharmaceuticals or Passage Bio?

Acumen Pharmaceuticals (ABOS) is larger, with a market capitalization of $13.49M compared with $12.61M for Passage Bio (PASG).

Which stock has performed better over the past year, ABOS or PASG?

PASG returned -49.32% over the past 12 months, compared with -88.12% for ABOS (price return, excluding dividends). Past performance does not predict future results.

Are Acumen Pharmaceuticals and Passage Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons